Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F22%3A10441721" target="_blank" >RIV/00064203:_____/22:10441721 - isvavai.cz</a>

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=QcdJsj8oTc" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=QcdJsj8oTc</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2021.279507" target="_blank" >10.3324/haematol.2021.279507</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS

Popis výsledku v původním jazyce

In neonates with myeloid hyperproliferation, apart from benign causes, Down syndrome (DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML) are considered. Besides TAM, rarely, non-DS related transient myeloproliferative diseases occur, making clinical decisions challenging.4 TAM, according to World Health Organization (WHO) classification, only applies to children with (mosaic) Down syndrome.5 In the past, different terminology has been used in non-DS patients, such as transient myeloproliferative disease (TMD) and transient leukemia. Since distinction from TAM is important, and it is challenging to determine whether this disease will be transient, the consensus group introduced the novel term &apos;infantile myeloproliferative disease&apos; (IMD), in order to distinguish it from TAM. Both TAM and IMD can usually be managed with a &apos;watch and wait&apos; strategy, while most fullblown AML or JMML cases require intensive treatment. We collected rare IMD cases from study groups collaborating in the International Berlin-Frankfurt-Münster AML Study Group (I-BFM AML SG). In addition, we reviewed the literature for neonatal cases of malignant myeloid hyperproliferation without DS. Based on these data, we developed, together with I-BFM AML SG and the European Working Group of Myelodysplastic syndromes in Childhood (EWOG-MDS) members, by consensus, clinical recommendations for the diagnostic approach and current adequate classification of malignant myeloid hyperproliferation in infancy. This is meant guiding clinicians in choosing the right strategy, i.e., whether to &apos;watch and wait&apos; or start highly intensive treatment in individual cases.

Název v anglickém jazyce

Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS

Popis výsledku anglicky

In neonates with myeloid hyperproliferation, apart from benign causes, Down syndrome (DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML) are considered. Besides TAM, rarely, non-DS related transient myeloproliferative diseases occur, making clinical decisions challenging.4 TAM, according to World Health Organization (WHO) classification, only applies to children with (mosaic) Down syndrome.5 In the past, different terminology has been used in non-DS patients, such as transient myeloproliferative disease (TMD) and transient leukemia. Since distinction from TAM is important, and it is challenging to determine whether this disease will be transient, the consensus group introduced the novel term &apos;infantile myeloproliferative disease&apos; (IMD), in order to distinguish it from TAM. Both TAM and IMD can usually be managed with a &apos;watch and wait&apos; strategy, while most fullblown AML or JMML cases require intensive treatment. We collected rare IMD cases from study groups collaborating in the International Berlin-Frankfurt-Münster AML Study Group (I-BFM AML SG). In addition, we reviewed the literature for neonatal cases of malignant myeloid hyperproliferation without DS. Based on these data, we developed, together with I-BFM AML SG and the European Working Group of Myelodysplastic syndromes in Childhood (EWOG-MDS) members, by consensus, clinical recommendations for the diagnostic approach and current adequate classification of malignant myeloid hyperproliferation in infancy. This is meant guiding clinicians in choosing the right strategy, i.e., whether to &apos;watch and wait&apos; or start highly intensive treatment in individual cases.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Haematologica

ISSN

0390-6078

e-ISSN

—

Svazek periodika

107

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

4006

Strana od-do

759-4764

Kód UT WoS článku

000811240400056

EID výsledku v databázi Scopus

2-s2.0-85125554397